Kamlesh Khunti: GLP-1 and SGLT2 in T2D – Discontinuation, Reinitiation and Switching Swedish registry data

Kamlesh Khunti, Professor of Primary Care Diabetes and Vascular Medicine, GP, University of Leicester, shared a post on X:

“GLP-1 and SGLT2 in T2D: Discontinuation, Reinitiation and Switching Swedish registry data

Discontinuation

GLP-1 RA: 24% at 1 yr, 39% at 3 yrs
SGLT2i: 28% at 1 yr, 46% at 3 yrs

Despite high discontinuation, 70–80% remained on therapy long term.”

Title: Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes

Authors: Carl-Emil Lim, Björn Pasternak, Björn Eliasson, Peter Ueda

Read Full Article.

More posts featuring GLP-1 on OncoDaily.